Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI ® (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma
RARITAN, New Jersey, January 27, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Phase 3 CARTITUDE-4 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) versus pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd) for the treatment of patients with relapsed and lenalidomide-refractory multiple myeloma met its primary endpoint of significant improvement in progression-free survival (PFS) at the first pre-specified interim analysis. As a result of meeting the primary endpoint, the Independent Data Monitoring Commi...
Source: Johnson and Johnson - January 27, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
How Recently Approved Tocilizumab Treats Covid-19
The FDA recently approved the drug Tocilizumab for use in hospitalized adults with severe Covid. Here we take a closer look at the data behind the approval. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - December 28, 2022 Category: Pharmaceuticals Authors: William A. Haseltine, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & Source Type: news
FDA Approves Monoclonal Antibody To Treat COVID-19 For First Time | ZeroHedge
FDA Approves Monoclonal Antibody To Treat COVID-19 For First Time Authored by Mimi Nguyen Ly via The Epoch Times (emphasis ours), The U.S. Food and Drug Administration (FDA) has, for the first time, approved a monoclonal antibody to treat COVID-19 in hospitalized patients. The logo of Swiss…#brazil #roche #basel #newzealand #rochesactemra #ghana #miminguyenly #mexico #healthcare #actemra (Source: Reuters: Health)
Source: Reuters: Health - December 24, 2022 Category: Consumer Health News Source Type: news
New Monoclonal Antibody Fully Approved For The Treatment Of Covid-19
The Food and Drug Administration has approved Tocilizumab for use against moderate to severe Covid-19 symptoms. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - December 22, 2022 Category: Pharmaceuticals Authors: William A. Haseltine, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & Source Type: news
Genentech's Actemra approved for hospitalized Covid-19 patients
The drug, already approved for other conditions, had won an emergency use authorization from the FDA in June 2021. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - December 21, 2022 Category: Health Management Authors: Ron Leuty Source Type: news
FDA Approves Genentech ’s Actemra for the Treatment of COVID-19 in Hospitalized Adults
South San Francisco, CA -- December 21, 2022 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Actemra® (tocilizumab)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 21, 2022 Category: Drugs & Pharmacology Source Type: news
FDA approves Roche ’s Actemra for the treatment of COVID-19 in hospitalised adults
Actemra is the first FDA-approved monoclonal antibody to treat COVID-19Since the beginning of the pandemic, more than one million peoplehospitalised with COVID-19 have been treated withActemra worldwideActemra is approved for this use in more than 30 countries for the treatment of COVID-19Basel, 21 December 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Actemra ® (tocilizumab) intravenous (IV) for the treatment of COVID-19 in hospitalised adult patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasi...
Source: Roche Media News - December 21, 2022 Category: Pharmaceuticals Source Type: news
Dr Reddy's Lab completes Phase 1 study of proposed arthritis drug
Dr Reddy's Laboratories Ltd on Monday said it has successfully completed the Phase 1 study of its proposed biosimilar of Tocilizumab to be used in the treatment of rheumatoid arthritis in adults. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 19, 2022 Category: Pharmaceuticals Source Type: news
Interleukin-6 inhibitors (tocilizumab or sarilumab) for adult patients hospitalised due to COVID-19, DHSC (updated 29th November 2022)
Published policy has been updated following recommendations of the updated WHO clinical guideline. An IL-6 inhibitor may be administered in combination with baricitinib (as well as corticosteroids, unless contraindicated) as per clinical judgement in severe or critical COVID-19. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - November 30, 2022 Category: Consumer Health News Source Type: news
Tocilizumab for Relapsing and Remitting Giant Cell Arteritis Tocilizumab for Relapsing and Remitting Giant Cell Arteritis
This case series highlights the development and delivery of an effective hub and referral pathway for the use of tocilizumab in patients with refractory or relapsing giant cell arteritis.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 14, 2022 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news
Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio
RARITAN, N.J., November 3, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today announced that abstracts from more than 50 company-sponsored studies, plus more than 20 investigator-initiated studies, will be presented at the American Society of Hematology (ASH) Annual Meeting in New Orleans from December 10-13, 2022. Janssen’s commitment to advancing an innovative portfolio of therapies for healthcare professionals and patients is evidenced through more than 70 presentations that span clinical studies and r...
Source: Johnson and Johnson - November 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Roche to present data at ASH 2022 showcasing strength of haematology portfolio and expanding into new areas to address more patient needs
Interim data from phase III HAVEN 7 study reinforceHemlibra ’s efficacy and safety in infants with severehaemophilia A without factor VIII inhibitors1New and updated data support use ofPolivy in diffuse large B-cell lymphoma, including its potential as a treatment option for previously untreated patients2New and updated data for innovative CD20xCD3 T-cell engaging bispecific antibodiesLunsumio andglofitamab further enhance their potential as effective, off-the-shelf, fixed-duration treatment options for people with lymphoma3,4,5,6,7First phase III data forcrovalimab show the co-primary efficacy endpoints were met, with s...
Source: Roche Media News - November 3, 2022 Category: Pharmaceuticals Source Type: news
Roche to present data at ASH 2022 showcasing strength of haematology portfolio and expanding into new areas to address more patient needs
Interim data from phase III HAVEN 7 study reinforceHemlibra ’s efficacy and safety in infants with severehaemophilia A without factor VIII inhibitors1New and updated data support use ofPolivy in diffuse large B-cell lymphoma, including its potential as a treatment option for previously untreated patients2New and updated data for innovative CD20xCD3 T-cell engaging bispecific antibodiesLunsumio andglofitamab further enhance their potential as effective, off-the-shelf, fixed-duration treatment options for people with lymphoma3,4,5,6,7First phase III data forcrovalimab show the co-primary efficacy endpoints were met, with s...
Source: Roche Investor Update - November 3, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche records solid results for the first nine months of 2022
Group salesup 2%[1] at constant exchange rates (CER) and 1% in Swiss francs; as expected, significantly lower COVID-19-related sales in both divisions in the third quarterSales in the Pharmaceuticals Divisionat the previous year ’s level with significantly lower sales of COVID-19-related products (Ronapreve and Actemra/RoActemra) and losses to biosimilars, offset by strong growth of newer medicinesSales in the Diagnostics Divisionrise 6%; base business remains strong; as expected, demand for COVID-19 tests sharply down in third quarterHighlights in the third quarter:EU approval forVabysmo (severe eye diseases)US approval...
Source: Roche Investor Update - October 18, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche records solid results for the first nine months of 2022
Basel, 18 October 2022Group salesup 2%1 at constant exchange rates (CER) and 1% in Swiss francs; as expected, significantly lower COVID-19-related sales in both divisions in the third quarterSales in the Pharmaceuticals Divisionat the previous year ’s level with significantly lower sales of COVID-19-related products (Ronapreve and Actemra/RoActemra) and losses to biosimilars, offset by strong growth of newer medicinesSales in the Diagnostics Divisionrise 6%; base business remains strong; as expected, demand for COVID-19 tests sharply down in third quarterHighlights in the third quarter:EU approval forVabysmo (severe eye ...
Source: Roche Media News - October 18, 2022 Category: Pharmaceuticals Source Type: news
